Your browser doesn't support javascript.
loading
Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8+ T cells.
Corria-Osorio, Jesus; Carmona, Santiago J; Stefanidis, Evangelos; Andreatta, Massimo; Ortiz-Miranda, Yaquelin; Muller, Tania; Rota, Ioanna A; Crespo, Isaac; Seijo, Bili; Castro, Wilson; Jimenez-Luna, Cristina; Scarpellino, Leonardo; Ronet, Catherine; Spill, Aodrenn; Lanitis, Evripidis; Romero, Pedro; Luther, Sanjiv A; Irving, Melita; Coukos, George.
Afiliación
  • Corria-Osorio J; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland. angeldejesus.corriaosorio@unil.ch.
  • Carmona SJ; AGORA Cancer Research Center, Lausanne, Switzerland. angeldejesus.corriaosorio@unil.ch.
  • Stefanidis E; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.
  • Andreatta M; AGORA Cancer Research Center, Lausanne, Switzerland.
  • Ortiz-Miranda Y; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.
  • Muller T; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.
  • Rota IA; AGORA Cancer Research Center, Lausanne, Switzerland.
  • Crespo I; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.
  • Seijo B; AGORA Cancer Research Center, Lausanne, Switzerland.
  • Castro W; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.
  • Jimenez-Luna C; AGORA Cancer Research Center, Lausanne, Switzerland.
  • Scarpellino L; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.
  • Ronet C; AGORA Cancer Research Center, Lausanne, Switzerland.
  • Spill A; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.
  • Lanitis E; AGORA Cancer Research Center, Lausanne, Switzerland.
  • Romero P; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.
  • Luther SA; AGORA Cancer Research Center, Lausanne, Switzerland.
  • Irving M; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne; and Department of Oncology, Lausanne University Hospital, Epalinges, Switzerland.
  • Coukos G; AGORA Cancer Research Center, Lausanne, Switzerland.
Nat Immunol ; 24(5): 869-883, 2023 05.
Article en En | MEDLINE | ID: mdl-37081150
ABSTRACT
To date, no immunotherapy approaches have managed to fully overcome T-cell exhaustion, which remains a mandatory fate for chronically activated effector cells and a major therapeutic challenge. Understanding how to reprogram CD8+ tumor-infiltrating lymphocytes away from exhausted effector states remains an elusive goal. Our work provides evidence that orthogonal gene engineering of T cells to secrete an interleukin (IL)-2 variant binding the IL-2Rßγ receptor and the alarmin IL-33 reprogrammed adoptively transferred T cells to acquire a novel, synthetic effector state, which deviated from canonical exhaustion and displayed superior effector functions. These cells successfully overcame homeostatic barriers in the host and led-in the absence of lymphodepletion or exogenous cytokine support-to high levels of engraftment and tumor regression. Our work unlocks a new opportunity of rationally engineering synthetic CD8+ T-cell states endowed with the ability to avoid exhaustion and control advanced solid tumors.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Interleucina-2 / Linfocitos T CD8-positivos / Neoplasias Experimentales Límite: Animals Idioma: En Revista: Nat Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Suiza

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Interleucina-2 / Linfocitos T CD8-positivos / Neoplasias Experimentales Límite: Animals Idioma: En Revista: Nat Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Suiza